首页/数据集/Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

NIAID Data Ecosystem2026-05-17 收录

黑色素瘤治疗

MAPKi耐药机制

数据链接：

https://figshare.com/articles/dataset/Supplementary_Table_S1-S3_from_Recurrent_Tumor_Cell_Intrinsic_and_Extrinsic_Alterations_during_MAPKi-Induced_Melanoma_Regression_and_Early_Adaptation/22532609 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Table S1-S3

应用场景：

创建时间：

2017-11-01

黑色素瘤治疗

不良事件分析

Background: Head-to-head evidence is lacking in comparative risks of high-grade adverse events (AEs) among different systemic treatment options for advanced melanoma. Methods: An up-to-date systematic

NIAID Data Ecosystem40

A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability

miRNA疗法

黑色素瘤治疗

Malignant melanoma is an aggressive form of skin cancer with poor prognosis. Despite improvements in awareness and prevention of this disease, its incidence is rapidly increasing. MicroRNAs (miRNAs) a

NIAID Data Ecosystem30

Intraocular Melanoma Treatment Market Size, Share 2024-2032

黑色素瘤治疗

医疗市场

The global intraocular melanoma treatment market is being aided by the global eye cancer market, which is projected to grow at a CAGR of 7.9% in the forecast period of 2024-2032.

www.expertmarketresearch.com20

Data_Sheet_1_Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.PDF

黑色素瘤治疗

免疫疗法

Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic

NIAID Data Ecosystem40

Gene expression profiling of melanoma cell lines (carrying NF1 loss-of-function) treated with DMSO (vehicle), MTX-216, MTX-211, trametinib, the combination of MTX-216 and trametinib, or pictilisib. Gene expression profiling of melanoma cell lines (carrying NF1 loss-of-function) treated with DMSO (vehicle), MTX-216, MTX-211, trametinib, the combination of MTX-216 and trametinib, or pictilisib

基因表达分析

黑色素瘤治疗

In this study, we identified a multi-kinase inhibitor MTX-216 to be efficacious in blocking NF1 loss-of-function melanoma cells. To identify the mechansisms of action of MTX-216, we treated NF1 loss-o

NIAID Data Ecosystem20

Supplementary Table S1-S3 from Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

资源简介：

相关数据集